Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Matinas BioPharma Holdings Inc MTNB

Healthcare Biotechnology
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:MTNB)

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

GlobeNewswire October 31, 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire August 14, 2024

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

GlobeNewswire August 7, 2024

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

GlobeNewswire June 24, 2024

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

GlobeNewswire June 13, 2024

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

GlobeNewswire May 16, 2024

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire May 9, 2024

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

GlobeNewswire May 7, 2024

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

GlobeNewswire May 2, 2024
View More News ››

Opinion & Analysis (NYSEAM:MTNB)

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

Streetwise Reports October 23, 2019

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

Streetwise Reports March 25, 2019
View More Opinion ››

Bullboard Posts (NYSEAM:MTNB)

Matinas BioPharma Holdings, Inc. (MTNB): Unlocking the Poten

http://beyondspx.com/2024/07/31/matinas-biopharma-holdings-inc-mtnb-unlocking-the-potential-of-lipid-nanocrystal-platform-delivery...
MikeTester - August 2, 2024

Matinas BioPharma Reports Successful Treatment of Patient wi

Breaking News: $MTNB Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203...
whytestocks - June 24, 2024

Matinas BioPharma Provides Positive Outcomes Update on the M

BREAKING NEWS: $MTNB Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program...
whytestocks - February 26, 2024

RE:it's time to go up again

Matinas BioPharma (NYSEMKT:MTNB) is up 4% postmarket following a start at Buy by SunTrust Robinson Humphrey. The firm's set its...
panda55 - January 24, 2020

it's time to go up again

for this one,so glta.
coolfooldumbguy - January 21, 2020

added more of this one

it has been almost a year and this one was up big time last spring,should have sold it then,but it is going up again ,so doubling down on...
coolfooldumbguy - September 25, 2019
View more Bullboard ››

Grid Battery Metals Inc.

Grid Battery Metals Inc.

Grid Battery Metals Inc. is a Canada-based exploration company. The Company focuses on exploration for high-value battery ...
View More »